Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Change in Receivables (2023 - 2025)

Historic Change in Receivables for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $2.6 million.

  • Monte Rosa Therapeutics' Change in Receivables rose 12913.58% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year increase of 92582.16%. This contributed to the annual value of -$332000.0 for FY2024, which is 8249.87% up from last year.
  • Per Monte Rosa Therapeutics' latest filing, its Change in Receivables stood at $2.6 million for Q3 2025, which was up 12913.58% from $961000.0 recorded in Q2 2025.
  • Monte Rosa Therapeutics' 5-year Change in Receivables high stood at $9.0 million for Q2 2024, and its period low was -$8.9 million during Q3 2024.
  • Moreover, its 3-year median value for Change in Receivables was $195000.0 (2023), whereas its average is $233000.0.
  • Its Change in Receivables has fluctuated over the past 5 years, first tumbled by 227600.0% in 2024, then skyrocketed by 1225000.0% in 2025.
  • Over the past 3 years, Monte Rosa Therapeutics' Change in Receivables (Quarter) stood at $336000.0 in 2023, then crashed by 225.6% to -$422000.0 in 2024, then skyrocketed by 715.17% to $2.6 million in 2025.
  • Its Change in Receivables was $2.6 million in Q3 2025, compared to $961000.0 in Q2 2025 and $1.2 million in Q1 2025.